CFGS
AIMT

Concourse Financial Group Securities’s Aimmune Therapeutics AIMT Stock Holding History

Concourse Financial Group Securities’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-93
Closed -$1.98K – 2307
2020
Q2 		$2K Hold
93
– – ﹤0.01% 1964
2020
Q1 		$1K Hold
93
– – ﹤0.01% 2141
2019
Q4 		$3K Buy
+93
New +$2.6K ﹤0.01% 1849

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Concourse Financial Group Securities's AIMT Position: Q3 2020 in Review

Concourse Financial Group Securities sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 93 shares — an estimated $1.98K sold.

Concourse Financial Group Securities first reported a position in AIMT in Q4 2019 and held it in 3 quarters. The position peaked at $3K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Concourse Financial Group Securities reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Concourse Financial Group Securities sold 93 Aimmune Therapeutics shares in Q3 2020, an estimated $1.98K.
  • Concourse Financial Group Securities first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 3 quarters.
  • Concourse Financial Group Securities's Aimmune Therapeutics position peaked at $3K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Concourse Financial Group Securities's 13F filing for Q3 2020, filed 13 Nov 2020.